|

The Titian cardiac electrophysiology surgical navigation system, developed by Meio Medical. [Photo/tidenews.com.cn]

The Titian cardiac surgery robot, a breakthrough in China's medical technology sector developed by Meio Medical in Shaoxing, East China's Zhejiang province, has received market approval from the National Medical Products Administration.

The approval marks a key step in China's independent innovation in high-end medical equipment and provides a safer, more precise domestic treatment option for millions of patients suffering from cardiac arrhythmia.

Compared with traditional procedures, this robotic system offers unmatched precision and stability during cardiac interventions. Its approval signifies that the device has moved beyond laboratory and clinical trials into actual medical practice, drawing widespread attention from the cardiology community.

According to Chang Dong, director of the Department of Cardiology at Shaoxing People's Hospital, the system replicates the coordinated movements of a surgeon's hands via two robotic arms, enabling highly stable, precise catheter manipulation that significantly improves the safety and consistency of procedures.

The device has completed clinical trials in several leading hospitals in China, with over 200 atrial fibrillation ablation procedures performed. A 12-month follow-up study showed that robot-assisted surgeries reduced the recurrence rate of atrial fibrillation by about 5.2 percent compared with conventional methods.

China has an estimated 20 million atrial fibrillation patients, with most medical resources concentrated in major cities. Chang noted that the system can also shorten surgeons' learning curves and, through its remote operation capabilities, expand access to high-quality cardiac care in regions with limited medical resources.